Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity

University of Minnesota (UMN) logo

University of Minnesota (UMN)

Status

Completed

Conditions

Cardiotoxicity

Study type

Observational

Funder types

Other

Identifiers

NCT02798679
CV-2016-24434

Details and patient eligibility

About

The purpose of this study is to determine whether pre-existing cardiac fibrosis is a predictor of cancer treatment-related cardiotoxicity.

Enrollment

40 patients

Sex

All

Ages

45+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Stage I-III breast cancer or lymphoma with a >2 year life expectancy
  • A treatment plan that includes anthracyclines and/or trastuzumab
  • Age >45 years
  • Able to hold breath for 10 seconds
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion criteria

  • Refusal or inability to provide informed consent
  • Known heart failure or LVEF <50%
  • Heart rate over 100 bpm
  • Renal dysfunction with GFR <30 mL/min/1.73m2
  • Participants with pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices
  • Symptomatic claustrophobia
  • Plans to move within 24 months of enrollment

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems